Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has approved Keytruda Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the… read more.
Merck Inc., known as MSD outside of the United States and Canada, and Eisai announced that the Phase III LEAP-001 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima,… read more.
AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated (BRCAm) castration-resistant prostate cancer… read more.
The FDA has approved pembrolizumab (Keytruda) in combination with lenvatinib (Lenvima) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),… read more.
Merck Inc announced that the Phase III KEYNOTE-716 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
